| Pipeline
page-template-default,page,page-id-14,ajax_updown_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-,qode-theme-ver-16.6,qode-theme-bridge,disabled_footer_top,wpb-js-composer js-comp-ver-5.5.5,vc_responsive


Vaccibody is currently testing it’s lead product candidate, VB10.16, to treat HPV16-induced precancerous cervical lesions in a clinical phase I/IIa study. The study is fully enrolled, and interim six months results are available.

Vaccibody is also developing individualised therapeutic cancer vaccines against tumour specific antigens, called neoantigens, arising from somatic gene mutations in malignant cells during neoplastic transformation. The investigational medicinal product (IMP), named VB10.NEO, is intended for use as therapeutic vaccination in patients with locally advanced or metastatic solid tumours.

Moreover, Vaccibody has compelling preclinical data within cancer and infectious diseases.